Changchun High-Tech Industry (Group) Co., Ltd. (SHE:000661)
China · Delayed Price · Currency is CNY | Market Cap | 34.19B -15.0% |
| Revenue (ttm) | 11.67B -12.1% |
| Net Income | -41.99M |
| EPS | -0.11 |
| Shares Out | 401.71M |
| PE Ratio | n/a |
| Forward PE | 33.51 |
| Dividend | 0.16 (0.19%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 3,346,558 |
| Average Volume | 4,287,318 |
| Open | 85.30 |
| Previous Close | 85.11 |
| Day's Range | 84.93 - 85.86 |
| 52-Week Range | 83.75 - 141.77 |
| Beta | 0.57 |
| RSI | 42.74 |
| Earnings Date | Apr 22, 2026 |
About SHE:000661
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal spray live attenuated influenza; xueshuanxinmaining tablet; and yinhuamiyanling tablet. It also develops real estate properties. The company was foun... [Read more]
Financial Performance
In 2025, SHE:000661's revenue was 12.08 billion, a decrease of -10.27% compared to the previous year's 13.47 billion. Earnings were 154.97 million, a decrease of -94.00%.
Financial StatementsNews
Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion
A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds ...